Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | $2.71 | $2.72 | $2.71 |
Q2 2024 | 2 | $2.88 | $2.88 | $2.88 |
Q3 2024 | 2 | $2.67 | $2.69 | $2.68 |
Q4 2024 | 7 | $2.34 | $2.47 | $2.40 |
Q1 2025 | 6 | $2.94 | $3.07 | $3.00 |
Q2 2025 | 5 | $3.16 | $3.25 | $3.20 |
Q3 2025 | 5 | $3.05 | $3.13 | $3.08 |
Q4 2025 | 5 | $2.69 | $2.76 | $2.72 |
Q1 2026 | 2 | $3.29 | $3.38 | $3.32 |
Q2 2026 | 2 | $3.48 | $3.58 | $3.52 |
Q3 2026 | 2 | $3.42 | $3.51 | $3.46 |
Q4 2026 | 2 | $3.11 | $3.19 | $3.14 |
IDEXX Laboratories, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $2.8 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.12. The company had revenue of 975.54 M for the quarter and had revenue of 3.66 B for the year. IDEXX Laboratories, Inc. has generated $10 earnings per share over the last year ($10.06 diluted earnings per share) and currently has a price-to-earnings ratio of 39.3. IDEXX Laboratories, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 3rd, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/31/2024 | Q3 2024 | $2.68 | $2.83 | 0.15 | $980.32 M | $975.54 M |
08/06/2024 | Q2 2024 | $2.88 | $2.46 | -0.42 | $1.01 B | $1.00 B |
05/01/2024 | Q1 2024 | $2.67 | $2.84 | 0.17 | $964.10 M | |
02/22/2024 | Q4 2023 | $2.34 | $901.60 M | |||
11/01/2023 | Q3 2023 | $2.37 | $2.55 | 0.18 | $926.88 M | $915.53 M |
08/01/2023 | Q2 2023 | $2.47 | $2.70 | 0.23 | $934.59 M | $943.63 M |
05/02/2023 | Q1 2023 | $2.42 | $2.58 | 0.16 | $900.20 M | |
02/16/2023 | Q4 2022 | $2.08 | $828.57 M | |||
11/01/2022 | Q3 2022 | $2.04 | $2.17 | 0.13 | $830.00 M | $841.66 M |
08/02/2022 | Q2 2022 | $1.56 | $1.57 | 0.01 | $863.14 M | $860.55 M |
05/04/2022 | Q1 2022 | $2.26 | $2.30 | 0.04 | $836.55 M | |
02/16/2022 | Q4 2021 | $1.92 | $801.09 M | |||
11/02/2021 | Q3 2021 | $1.91 | $2.06 | 0.15 | $797.61 M | $810.42 M |
07/30/2021 | Q2 2021 | $2.02 | $2.37 | 0.35 | $788.86 M | $826.14 M |
05/04/2021 | Q1 2021 | $1.72 | $2.39 | 0.67 | $777.71 M | |
02/12/2021 | Q4 2020 | $2.04 | $720.94 M | |||
10/29/2020 | Q3 2020 | $1.43 | $1.71 | 0.28 | $672.48 M | $721.79 M |
07/31/2020 | Q2 2020 | $1.17 | $1.75 | 0.58 | $593.05 M | $637.59 M |
04/30/2020 | Q1 2020 | $1.20 | $1.31 | 0.11 | $626.34 M | |
02/14/2020 | Q4 2019 | $1.05 | $605.45 M |
IDEXX Laboratories, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 3rd, 2025 based off last year's report dates.
In the previous quarter, IDEXX Laboratories, Inc. (:IDXX) reported $2.8 earnings per share (EPS) to beat the analysts' consensus estimate of $2.68 by $0.12.
The conference call for IDEXX Laboratories, Inc.'s latest earnings report can be listened to online.
The conference call transcript for IDEXX Laboratories, Inc.'s latest earnings report can be read online.
IDEXX Laboratories, Inc. (:IDXX) has a recorded annual revenue of $3.66 B.
IDEXX Laboratories, Inc. (:IDXX) has a recorded net income of $3.66 B. IDEXX Laboratories, Inc. has generated $10.17 earnings per share over the last four quarters.
IDEXX Laboratories, Inc. (:IDXX) has a price-to-earnings ratio of 39.3 and price/earnings-to-growth ratio is 14.3.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED